Nikhila Kethireddy

Breast medical oncologist @cityofhope⬅️Harbor-UCLA Heme/onc grad ‘23⬅️UCONN IM grad ‘20. Run for fun🏃🏾‍♀️Views are my own!

[Ade Adamson, MD MPP @AdeAdamson]

This is CRAZY. The test didn’t meet its endpoint and the study was not designed to assess harm and showed no benefit.

https://t.co/WQT8rbDEZb

[Stephen V Liu, MD @StephenVLiu]

Electronic health records and messages have a major impact on physician workload - though often invisible and underestimated. Report @JCOOP_ASCO show that every patient EHR messages leads to ~7 internal in-basket messages. Contribution to burnout?

https://t.co/bkDXQLo4Bc

[Hope Rugo @hoperugo]

Finally!! Sheparding in a new era. FDA Grants Accelerated Approval to a New Breast Cancer Treatment @oncoalert https://t.co/lEGrnWoTua

[Yakup Ergün @dr_yakupergun]

First-line ivonescimab+taxane in advanced TNBC (n=36): ORR 80%, mPFS 15.2 mo. In CPS<10 disease, ORR was 79.3% and mPFS 13 mo—the key signal. Promising, but a small single-arm phase 2. Its place in the ASCENT-03/04 and Dato-DXd era needs phase 3 validation.

https://t.co/5fYxg9bShV

[Hope Rugo @hoperugo]

Thank you! The ongoing swish trial will help to define the benefit of the steroid mouthwash in preventing Dato DXd stomatitis in lung and breast cancer.

[Hope Rugo @hoperugo]

So proud of our @cityofhope team at the ASCO quality training program in SFO. They won the team building event! Their project is to increase somatic testing in HR+ MBC. @Jenn_Tseng Leah Naghi and @NikhilaKeth thanks to @ASCO for this great opportunity.

[Nikhila Kethireddy @NikhilaKeth]

@hoperugo @montypal @stage4kelly @CancerCareMASCC @OncoAlert Congratulations 🎉 Dr. @hoperugo

[Hope Rugo @hoperugo]

@stage4kelly @CancerCareMASCC Thank you! Grateful for this kind recognition from #MASCC26. @OncoAlert

[Giampaolo Bianchini @BianchiniGP]

🔥 More is not always the best

REDUCE trial demonstrated that every 12 weeks denosumab is not inferior to standard every 4 weeks

✅ Non inferior efficacy
✅ Improved safety profile
✅ Reduce cost

I love this type of trials!
Congratulations to all investigators

[Hope Rugo @hoperugo]

Hitting the Mark — Individualizing Therapy for HER2-Positive Early-Stage Breast Cancer | New England Journal of Medicine https://t.co/OPgIQaK7PF

[Paolo Tarantino @PTarantinoMD]

@allisonoconn @DrHBurstein @stolaney1 @PhilipPoorvu We now have the option of giving 4 cycles of neoadjuvant T-DXd (followed by THP, DB11 regimen) or give NACT, go to surgery, and only give adjuvant T-DXd (14 cycles, DB05 regimen) for patients with high-risk RD. Only the second trial war powered for iDFS, but both are very active!

[JAMA @JAMA_current]

US nonprofit hospitals spent $7.8 billion on management consultants from 2009 to 2023, but contracts were not associated with meaningful changes in finance, operations, or quality of care. 🧵

https://t.co/QQswMYxrG8

[Paolo Tarantino @PTarantinoMD]

BREAKING: positive results from the VIKTORIA-1 PIK3CA-mutant cohort

Both the gedatolisib triplet and doublet improved PFS vs fulv/alpelisib, positioning gedatolisib as an active option irrespective of PIK3CA status. Key caveat: the weekly IV formulation. https://t.co/ZclPhQmcWl

[Mikkael A. Sekeres MD, MS @MikkaelSekeres]

For our cancer survivors, we ask for “time with meaning, time with mobility, time with dignity. Time that is lived, not merely survived.” Superb essay by @GlopesMd @SylvesterCancer!! @statnews https://t.co/bqT3wyW1Rx via @statnews

[Hope Rugo @hoperugo]

@cityofhope well represented at #SABCS2025 - and more not in the pic! Great team, fabulous docs!

[Nikhila Kethireddy @NikhilaKeth]

@minasedrakmd @hoperugo @stolaney1 @AnnPartridgeMD @maryam_lustberg @ErikaHamilton9 @stales @Dr_RShatsky @hmcarthur @KalinskyKevin @fischmd Congratulations!

[Sara Tolaney @stolaney1]

lidERA phase 3 trial evaluating giredestrant (oral SERD) as adjuvant therapy in pts with ER+/HER2- BC met its primary endpoint at an interim analysis, showing a statistically significant improvement in iDFS. OS is immature but has a trend.

https://t.co/fnfWVqujRP

[Erika Hamilton, MD, FASCO @ErikaHamilton9]

#imlunestrant now FDA approved for ESR1m metastatic breast cancer #bcsm

This joins elacestrant in the approved camp. Several others at FDA for consideration currently.

@OncBrothers @OncoAlert

https://t.co/klz3UXyuw3

[Yakup Ergün @dr_yakupergun]

Dormant tumor cells in breast ca recurrence 🔬
CLEVER trial (n = 53, phase 2)

DTC ↓: HCQ 80% | EVE 78% | HCQ+EVE 87%
3y RFS: 91.7% | 92.9% | 100%

📌 HCQ shows biological activity, well tolerated
📌 EVE effective but toxic
📌 MRD-targeted therapy concept emerging
💬 Relies on bone marrow biopsies; less invasive MRD detection needed if efficacy holds.

https://t.co/xR1XCISfSV

[City of Hope @cityofhope]

Missed the July 28 Breast Cancer Forum hosted by @HopeRugo with experts @stolaney1 @veronicajonesMD @Stage4Kelly &amp; more.
🎥 Watch the recording to hear #ASCO25 research highlights and learn how new findings are shaping the future of care. Watch: https://t.co/wfiJCLlIOn